Cellectricon to discuss phenotypic assay designs for chronic pain research in webinar

Cellectricon explores novel phenotypic assay designs in a webinar, 5 September, 11am-12pm (EDT)

Cellectricon, a leading provider of advanced cell-based screening technologies and services, invites researchers to join the webinar entitled “Phenotypic Screening Strategies for Chronic Pain Research”, taking place on 5 September, 11:00 am to 12:00pm EDT. Investigating the latest approaches to phenotypic assay designs for drug discovery in chronic pain research, the webinar will explain how researchers can enhance neurobiology workflows using Cellectricon’s comprehensive phenotypic screening platform and highly relevant disease models. 

Dr Paul Karila (Head of Discovery Services, Cellectricon), and Dr Charlotta Blom (Senior Researcher, Cellectricon) will talk the viewers through the many benefits of using phenotypic assays for drug discovery in the treatment of chronic pain. Viewers will learn how to increase the chance of identifying modulators of a disease, even without information on the target. Furthermore, by focusing on downstream functional responses such as neuronal excitability, identifying novel mechanisms as well as compounds acting on the pain pathway is now possible.   

The webinar presents an ideal opportunity for researchers and lab managers to keep up to date with the most recent innovations in areas including neurobiology, translational science, drug discovery and electrophysiology. To discuss these technologies in more depth, Cellectricon will also be attending the 7th Annual Pain & Migraine Therapeutics Summit, 25-26 September in Boston (USA).